熱門資訊> 正文
Virios Therapeutics GAAP每股收益为-2.05美元
2024-11-07 22:55
- Virios Therapeutics press release (NASDAQ:DWTX): Q3 GAAP EPS of -$2.05.
- The company estimates that its current cash of $2M at Sept. 30 along with the $16.5M in loan proceeds received on Oct. 7 is not sufficient to fund operating expenses and capital requirements for at least the next 12 months.
- It will need to secure the additional $3M of loan proceeds available under the terms of the loan agreement in February 2025 to continue to fund operations through 2025.
- Shares -2.92%
More on Virios Therapeutics
- Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics
- Seeking Alpha’s Quant Rating on Virios Therapeutics
- Historical earnings data for Virios Therapeutics
- Financial information for Virios Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
